This Phase 3, multicenter, randomized, masked, controlled, parallel group study is designed to demonstrate that suprachoroidal (SC) CLS-TA administered with intravitreal (IVT) aflibercept (EYLEA® ; Regeneron; Tarrytown, NY and Bayer, Berlin, Germany) in subjects with treatment naive RVO is superior to IVT aflibercept used alone.